Management of Febrile Neutropenia in Patients Receiving Myelosuppressive Chemotherapy: Current Guidelines and Clinical Practice

[1]Nihala M, [2]Sreejith K, [3]Abdul Majeed K, [4]Athira T, [5]Nihala Jasmin K T

[1]M Pharm student, [2]Assistant Professor, [3]Professor of Medicine, [4]M Pharm Student, [5]M Pharm Student
[1]Department of Pharmacy Practice,
[1]Kerala University of Health Sciences, Thrissur, Kerala, India

Abstract: Febrile neutropenia (FN) is one of the most serious oncologic emergencies associated with myelosuppressive chemotherapy and is linked with significant morbidity, mortality, prolonged hospitalization, interruption of chemotherapy schedules, and increased healthcare costs. FN commonly develops in patients receiving cytotoxic chemotherapy for haematological malignancies and solid tumours, particularly during periods of severe neutropenia. Prompt recognition and evidence-based management are essential to reduce complications and improve treatment outcomes. Current international guidelines emphasize early risk identification, immediate initiation of empirical broad-spectrum antibiotics, appropriate microbiological investigations, and supportive care measures including granulocyte colony-stimulating factor (G-CSF) prophylaxis in selected high-risk patients. The use of validated scoring systems such as the Multinational Association for Supportive Care in Cancer (MASCC) score and Clinical Index of Stable Febrile Neutropenia (CISNE) assists clinicians in identifying patients suitable for outpatient management. Advances in antimicrobial therapy and infection prevention strategies have improved clinical outcomes in recent years. However, challenges including multidrug-resistant organisms, inappropriate antibiotic use, delayed diagnosis, and chemotherapy dose modifications continue to affect patient care. This review comprehensively discusses the epidemiology, pathophysiology, clinical presentation, risk assessment, current management guidelines, antimicrobial therapy, role of G-CSF prophylaxis, preventive strategies and emerging clinical practices in the management of febrile neutropenia among patients receiving myelosuppressive chemotherapy.

IndexTerms **-** Febrile neutropenia, myelosuppressive chemotherapy, granulocyte colony-stimulating factor, empirical antibiotics, MASCC score, supportive care.

INTRODUCTION

Febrile neutropenia (FN) is a potentially life-threatening complication commonly observed in cancer patients receiving cytotoxic chemotherapy.[1] It is characterized by the development of fever in association with neutropenia, which significantly compromises host immune defense mechanisms.[2] Neutrophils constitute a major component of innate immunity and are essential for the prevention and control of bacterial and fungal infections. Chemotherapy-induced suppression of bone marrow function frequently results in decreased neutrophil production, predisposing patients to severe infections.[2,3]

The incidence of febrile neutropenia varies depending on the type of malignancy, chemotherapy regimen, patient age, nutritional status, comorbidities, and performance status.[1,4] Hematological malignancies such as acute leukemia and lymphoma exhibit a particularly high risk of FN because of intensive myelosuppressive chemotherapy regimens. Similarly, patients receiving dose-dense or combination chemotherapy for breast cancer, lung cancer, and gastrointestinal malignancies are at increased risk.

FN remains a major cause of emergency hospitalization in oncology practice. Delayed diagnosis and treatment can rapidly progress to sepsis, septic shock, organ dysfunction, and death. Mortality rates are considerably higher among patients with prolonged neutropenia, advanced age, or documented bloodstream infections.[5,6] Furthermore, FN often necessitates chemotherapy dose reductions or delays, potentially compromising cancer treatment efficacy and overall survival.

Over the last two decades, the management of FN has evolved substantially with the development of evidence-based international guidelines from organizations such as the American Society of Clinical Oncology (ASCO), Infectious Diseases Society of America (IDSA), National Comprehensive Cancer Network (NCCN), and European Society for Medical Oncology (ESMO). These guidelines emphasize early initiation of empirical antimicrobial therapy, risk-adapted management, and prophylactic use of granulocyte colony-stimulating factors in selected high-risk populations.[8,11,22]

The increasing prevalence of multidrug-resistant organisms and invasive fungal infections has added complexity to FN management. At the same time, improved diagnostic tools, antimicrobial stewardship programs, and outpatient treatment strategies have enhanced patient outcomes and reduced healthcare burden.

This review article aims to provide a comprehensive overview of the current guidelines and clinical practice in the management of febrile neutropenia among patients receiving myelosuppressive chemotherapy.

FEBRILE NEUTROPENIA

Febrile neutropenia is defined as the occurrence of fever in a patient with neutropenia. According to IDSA guidelines, fever is defined as a single oral temperature of ≥38.3°C or a sustained temperature of ≥38.0°C for more than one hour. Neutropenia is defined as an absolute neutrophil count (ANC) <500 cells/mm3 or an ANC expected to decrease below 500 cells/mm3 within the next 48 hours.[2,3]

Neutropenia is further classified into:

Table1. Classification of neutropenia[16]

Type	ANC
Mild neutropenia	1000–1500 cells/mm3
Moderate neutropenia	500–1000 cells/mm3
Severe neutropenia	<500 cells/mm3
Profound neutropenia	<100 cells/mm3

The duration and severity of neutropenia are major determinants of infection risk. Patients with prolonged neutropenia lasting more than seven days are at substantially increased risk of invasive bacterial and fungal infections.

EPIDEMIOLOGY

FN is among the most common complications of cancer chemotherapy. The incidence varies widely depending on tumour type and chemotherapy intensity. Haematological malignancies have the highest rates because of profound and prolonged myelosuppression. Studies suggest that up to 80% of patients with hematologic cancers and approximately 10–50% of patients with solid tumours experience at least one episode of FN during chemotherapy.[17]

Several chemotherapy regimens are associated with high FN risk (>20%), including:

- CHOP and R-CHOP regimens
- Dose-dense breast cancer regimens
- Induction therapy for acute leukemia
- High-dose cyclophosphamide-based therapy
- Stem cell transplantation conditioning regimens

The burden of FN is particularly significant in low- and middle-income countries where limited healthcare infrastructure, delayed presentation, and restricted access to supportive care contribute to increased morbidity and mortality. Hospitalization due to FN is associated with considerable healthcare expenditure. Prolonged inpatient care, intensive antibiotic therapy, diagnostic investigations, and management of complications substantially increase treatment costs.[9]

PATHOPHYSIOLOGY OF FEBRILE NEUTROPENIA

Chemotherapy targets rapidly dividing cells, including malignant cells and normal bone marrow progenitor cells. Damage to hematopoietic stem cells results in decreased neutrophil production and impaired immune defense.[13] Bone marrow suppression, mucosal barrier injury, altered microbiome and impaired immune response leads to infection development in neutropenic patients.

Gram-positive organisms such as coagulase-negative staphylococci and staphylococcus aureus were historically predominant causes of fn. However, gram-negative bacteria including escherichia coli, klebsiella species, and pseudomonas aeruginosa continue to be associated with severe sepsis and increased mortality. Invasive fungal infections caused by candida and aspergillus species are particularly common in patients with prolonged neutropenia.[17,18]

RISK FACTORS FOR FEBRILE NEUTROPENIA

Patient-Related Risk Factors:

Advanced age emerged as a significant predictor of FN, reflecting age-related decline in bone marrow reserve and hematopoietic stem cell function, resulting in delayed neutrophil recovery following chemotherapy. The presence of comorbid conditions and poor performance status further increased susceptibility to FN. Poor nutritional status and chronic inflammation further compromise immune defense, facilitating progression from neutropenia to febrile infection.[7,8]

Disease-Related Risk Factors:

Disease-related characteristics such as advanced stage of lymphoma and high tumour burden were associated with an elevated risk of FN. Bone marrow involvement by lymphoma may further impair hematopoietic function, predisposing patients to severe neutropenia following chemotherapy. Elevated inflammatory cytokines in advanced NHL suppress normal hematopoiesis and impair neutrophil production.[12] Additionally, aggressive disease often necessitates intensive chemotherapy, compounding bone marrow suppression and increasing FN risk.[6]

Treatment-Related Risk Factors:

Treatment-related factors played a major role in FN development. The absence of primary G-CSF prophylaxis was strongly associated with increased FN incidence. G-CSF stimulates proliferation and differentiation of neutrophil precursors and shortens the duration of neutropenia. In its absence, prolonged neutrophil suppression occurs, increasing the window of vulnerability to infections and subsequent febrile episodes. FN events were more common during early chemotherapy cycles. During early cycles, bone marrow has not yet adapted to cytotoxic stress, leading to deeper neutrophil reduction and increased infection risk. Maintaining full-dose intensity without adequate supportive care increased the likelihood of FN.[2,4,5]

Laboratory-Related Risk Factors:

Baseline laboratory abnormalities, including low absolute neutrophil count, anemia, and hypoalbuminemia, were identified as important predictors of FN. These parameters may serve as practical clinical indicators for identifying high-risk patients prior to treatment initiation. Hypoalbuminemia also indicates systemic inflammation, which weakens immune competence and increases susceptibility to infection during neutropenia.[2,4]

RISK STRATIFICATION

Risk assessment plays a central role in FN management because it helps determine the need for hospitalization and intensity of treatment.

MASCC Risk Index Score

The MASCC scoring system identifies low-risk patients suitable for outpatient management.[24]

Table2. MASCC Risk Index Score[24]

Clinical Characteristic	Score
Burden of illness: No or mild symptoms	5
Burden of illness: Moderate symptoms	3
No hypotension (SBP >90 mmHg)	5
No chronic obstructive pulmonary disease	4
Solid tumor or no previous fungal infection	4
No dehydration requiring IV fluids	3
Outpatient status at onset of fever	3
Age <60 years	2

Score ≥ 21: Low-risk febrile neutropenia; outpatient/oral antibiotic therapy.

Score < 21: High-risk febrile neutropenia; requires inpatient management and IV antibiotics.

CISNE Score

The Clinical Index of Stable Febrile Neutropenia (CISNE) score is used particularly in clinically stable patients with solid tumors.

High-Risk Features; Patients with the following features are considered high risk:

- Profound neutropenia
- Neutropenia >7 days
- Hemodynamic instability

- Pneumonia
- Organ dysfunction
- Severe mucositis
- Abdominal symptoms
- Neurological changes

CURRENT GUIDELINES FOR MANAGEMENT

Several international organizations have published guidelines for FN management.

ASCO Guidelines

ASCO recommends primary G-CSF prophylaxis when the risk of FN exceeds 20% or when patients possess additional risk factors.[1,23]

IDSA Guidelines

IDSA emphasizes immediate empirical broad-spectrum antibiotic therapy within one hour of presentation.[1,23]

NCCN Guidelines

NCCN provides comprehensive recommendations regarding risk assessment, antimicrobial therapy, antifungal management, and outpatient treatment.[1,24]

ESMO Guidelines

ESMO advocates individualized treatment approaches based on patient risk profiles and local antimicrobial resistance patterns.[1,4,8]

Although recommendations vary slightly among organizations, all guidelines stress early intervention and risk-adapted therapy. High-risk patients require inpatient intravenous antibiotic therapy.

MANAGEMENT

Empirical Antimicrobial Therapy

Early administration of empirical antibiotics is the cornerstone of FN management. Delays beyond one hour are associated with increased mortality.

Recommended monotherapy agents include:

- Piperacillin-tazobactam
- Cefepime
- Meropenem
- Imipenem-cilastatin

These agents provide broad Gram-negative coverage including activity against Pseudomonas aeruginosa.

Role of Vancomycin

Vancomycin is not routinely recommended but may be added in cases of:

- Suspected catheter-related infection
- Hemodynamic instability
- Skin or soft tissue infection
- Pneumonia
- Methicillin-resistant Staphylococcus aureus colonization
- Combination Therapy

Combination regimens may be considered in unstable patients or settings with high antimicrobial resistance.

Oral Antibiotic Therapy

Low-risk patients may receive oral therapy with:

- Ciprofloxacin plus amoxicillin-clavulanate

Outpatient treatment requires careful monitoring and patient education.

Role of Granulocyte Colony-Stimulating Factors

Granulocyte colony-stimulating factors stimulate neutrophil production and reduce the incidence and duration of FN.

Commonly Used Agents

- Filgrastim
- Pegfilgrastim
- Lenograstim

Primary prophylaxis is recommended when the overall FN risk is ≥20%. Secondary prophylaxis is recommended in patients with previous FN episodes during maintenance of chemotherapy. G-CSF is usually administered 24–72 hours after chemotherapy completion.[7,8,11]

Benefits of G-CSF

- Reduced FN incidence
- Reduced hospitalization
- Lower infection-related mortality
- Improved chemotherapy dose intensity

Table 3: Indications for G-CSF Prophylaxis

Clinical Situation	Recommendation
FN risk >20%	Recommended
FN risk 10–20% with additional risk factors	Consider prophylaxis
FN risk <10%	Routine prophylaxis not recommended

Outpatient Management of Febrile Neutropenia

- Outpatient management preferred for low-risk patients with hemodynamic stability, caregiver support, access to emergency healthcare services and ability to tolerate oral medications. It reduces healthcare costs, hospital-acquired infections and improves patient comfort. However, strict follow-up and patient counseling are essential.

Supportive Care Measures

- Hydration and Electrolyte Management
- Nutritional Support
- Blood transfusions
- Mucositis Management

Infection Control Measures

- Hand hygiene
- Protective isolation in selected patients
- Environmental infection control

CLINICAL PRACTICE CHALLENGES

- Delayed presentation to healthcare facilities
- Limited access to G-CSF
- Increasing antimicrobial resistance
- Inadequate patient education
- Variability in adherence to guidelines
- Financial burden associated with hospitalization and supportive care

Developing standardized institutional protocols and improving clinician awareness may help optimize outcomes.

CONCLUSION

Febrile neutropenia remains a serious and potentially life-threatening complication of myelosuppressive chemotherapy. Early recognition, prompt empirical antibiotic therapy, accurate risk stratification, and appropriate supportive care are essential components of successful management. International guidelines from ASCO, IDSA, NCCN and ESMO provide evidence-based recommendations that have significantly improved patient outcomes.

The use of granulocyte colony-stimulating factors has reduced FN incidence and helped maintain chemotherapy dose intensity in high-risk patients. Advances in antimicrobial therapy, antifungal management, and outpatient care strategies continue to evolve clinical practice.

However, increasing antimicrobial resistance, financial constraints and variability in healthcare infrastructure remain major challenges, particularly in developing countries. Continued research, antimicrobial stewardship, and implementation of standardized treatment protocols are essential to improve the safety and quality of cancer care.

Abbreviations and Acronyms

FN: Febrile neutropenia
G-CSF: Granulocyte colony-stimulating factor
MASCC: Multinational Association for Supportive Care in Cancer
CISNE: Clinical Index of Stable Febrile Neutropenia
ASCO: American Society of Clinical Oncology
IDSA: Infectious Diseases Society of America
NCCN: National Comprehensive Cancer Network
ESMO: European Society for Medical Oncology
ANC: Absolute neutrophil count

ACKNOWLEDGMENT

The authors would like to express their sincere gratitude to the Kerala University of Health Sciences for providing the academic support and resources necessary to carry out this study. We extend our heartfelt thanks to the faculty members of the Department of Pharmacy Practice for their valuable guidance, constructive suggestions, and continuous encouragement throughout the course of this work. We also acknowledge all researchers and authors whose studies have contributed to the literature reviewed in this article. Finally, we thank our peers and well-wishers for their support during the preparation of this manuscript.

REFERENCES

1. Warsame M, Go RS, Godby R, Shaikh ME, Pruthi R. Global guidelines for febrile neutropenia management: A GRADE-based comparative analysis. JCO Oncology Practice. 2025 Oct;21(10_suppl):469–9.
2. Villafuerte-Gutierrez P, Villalon L, Losa JE, Henriquez-Camacho C. Corrigendum to “Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update.” Advances in Hematology. 2019 Jul 16;2019:1–2.
3. Punnapuzha S, Edemobi PK, Elmoheen A. Febrile Neutropenia [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541102/
4. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Annals of Oncology 2016; 27: v111-v118.
5. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases 2011; 52(4): e56-e93.
6. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy. Journal of Clinical Oncology 2018; 36(14): 1443-1453.
7. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors. Journal of Clinical Oncology 2015; 33(28): 3199-3212.
8. Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines. Annals of Oncology 2010; 21: v248-v251.
9. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia. Cancer 2006; 106(10): 2258-2266.
10. Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 2010; 116(23): 5555-5563.
11. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor. European Journal of Cancer 2011; 47(1): 8-32.
12. Yokoyama M, Kusano Y, Takahashi A, Inoue N, Ueda K, Nishimura N, et al. Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer [Internet]. 2017 Nov 1;25(11):3313–20.
13. Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. CA: A Cancer Journal for Clinicians [Internet]. 2011;61(5):n/a-n/a.
14. Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration in patients with febrile neutropenia. Antimicrobial Agents and Chemotherapy 2014; 58(7): 3799-3803.
15. Justiz Vaillant AA, Zito PM. Neutropenia [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507702/

16. Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Critical Reviews in Oncology/Hematology. 2014 Jun;90(3):190–9.
17. Bow EJ. Infection in neutropenic patients with cancer. Critical Care Clinics 2013; 29(3): 411-441.
18. Viscoli C, Varnier O, Machetti M. Infections in Patients with Febrile Neutropenia: Epidemiology, Microbiology, and Risk Stratification. Clinical Infectious Diseases. 2005 Apr 1;40(Supplement_4):S240–5.
19. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clinical Infectious Diseases 2004; 39(Suppl 1): S32-S37.
20. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients. Clinical Infectious Diseases 2002; 34(6): 730-751.
21. Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia. Supportive Care in Cancer 2014; 22(10): 3163-3171.
22. de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO guidelines. Annals of Oncology 2010; 21(Suppl 5): v252-v256.
23. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. Journal of Clinical Oncology. 2018 May 10;36(14):1443–53.
24. Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections. Journal of the National Comprehensive Cancer Network 2016; 14(7): 882-913.
25. Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038 3051.
26. Gudiol C, Bodro M, Simonetti A, et al. Changing epidemiology of bacteremia in neutropenic patients. Clinical Microbiology and Infection 2013; 19(5): 474-479.
27. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection. Annals of Internal Medicine 1966; 64(2): 328-340.
28. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia. Cancer 2004; 100(2): 228-237.
29. Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization. Cancer 2005; 103(9): 1916-1924.
30. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin prophylaxis during chemotherapy-induced neutropenia. New England Journal of Medicine 2005; 353(10): 977-987.
31. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients. Cochrane Database of Systematic Reviews 2012; 1: CD004386.
32. Taplitz RA, Kennedy EB, Flowers CR. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression. Journal of Clinical Oncology 2018; 36(30): 3043-3054.
33. Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery. Critical Reviews in Oncology/Hematology 2008; 68(2): 152-167.
34. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with G-CSF. Journal of Clinical Oncology 2007; 25(21): 3158-3167.
35. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis. Clinical Infectious Diseases 2008; 46(3): 327-360.
36. Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in bloodstream infections in patients with hematological malignancies. Clinical Infectious Diseases 2003; 36(9): 1103-1110.
37. Carmona-Bayonas A, Gomez J, Gonzalez-Billalabeitia E, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. British Journal of Cancer 2015; 112(4): 612-617.
38. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy in febrile neutropenic patients. Haematologica 2013; 98(12): 1826-1835.
39. Schwenkglenks M, Pettengell R, Jackisch C, et al. Risk factors for chemotherapy-induced febrile neutropenia. Annals of Oncology 2011; 22(12): 275-282.